Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6119726,Absorption half-life (t1/2 a),Absorption half-life (t1/2 a) averaged 24 min.,Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119726/),min,24,18761,DB00628,Clorazepate
,6119726,elimination half-life (t1/2 beta),"After a rapid phase of distribution, DMDZ elimination was slow, with a mean elimination half-life (t1/2 beta) of 82 h (range 27-219 h).",Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119726/),h,82,18762,DB00628,Clorazepate
,6119726,free fraction (FF),"The mean free fraction (FF) was 3.1% (range 2.0-4.3%), and increased significantly with declining plasma albumin concentrations (r=-0.57, P less than 0.001).",Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119726/),%,3.1,18763,DB00628,Clorazepate
,15234378,apparent half-life,"The neonatal blood concentrations of the clorazepate metabolites were very high at delivery (26 mg/l nordiazepam and 3.5 mg/l oxazepam) and showed little change over the next 5 days (16 mg/l nordiazepam and 2.1 mg/l oxazepam, with an apparent half-life of 168 h for nordiazepam and 160 h for oxazepam).",[Benzodiazepine poisoning in a neonate: clinical and toxicokinetic evaluation following enterodialysis with activated charcoal]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234378/),h,168,67971,DB00628,Clorazepate
,15234378,apparent half-life,"The neonatal blood concentrations of the clorazepate metabolites were very high at delivery (26 mg/l nordiazepam and 3.5 mg/l oxazepam) and showed little change over the next 5 days (16 mg/l nordiazepam and 2.1 mg/l oxazepam, with an apparent half-life of 168 h for nordiazepam and 160 h for oxazepam).",[Benzodiazepine poisoning in a neonate: clinical and toxicokinetic evaluation following enterodialysis with activated charcoal]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234378/),h,160,67972,DB00628,Clorazepate
,15234378,half-lifes,The nordiazepam and oxazepam half-lifes were reduced to 42 h and 30 h respectively.,[Benzodiazepine poisoning in a neonate: clinical and toxicokinetic evaluation following enterodialysis with activated charcoal]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234378/),h,42,67973,DB00628,Clorazepate
,15234378,half-lifes,The nordiazepam and oxazepam half-lifes were reduced to 42 h and 30 h respectively.,[Benzodiazepine poisoning in a neonate: clinical and toxicokinetic evaluation following enterodialysis with activated charcoal]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234378/),h,30,67974,DB00628,Clorazepate
,2859206,bioavailability,"The bioavailability of DPC and DZM after i.m. administration, determined from computer calculated AUCs, was 1.04 and 0.85, respectively.",Intramuscular bioavailability of chlorazepate as compared to diazepam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859206/),,1.04,80788,DB00628,Clorazepate
,2859206,bioavailability,"The bioavailability of DPC and DZM after i.m. administration, determined from computer calculated AUCs, was 1.04 and 0.85, respectively.",Intramuscular bioavailability of chlorazepate as compared to diazepam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859206/),,0.85,80789,DB00628,Clorazepate
,6415130,accumulation half-life,"Determination of diazepam and desmethyldiazepam plasma concentrations during the dosing period and for a withdrawal period indicated that accumulation half-life for both diazepam (7.8 days in obese vs. 3.1 days in normal subjects, P less than 0.05) and desmethyldiazepam (30.3 vs.",Prolonged accumulation of diazepam in obesity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),d,7.8,90011,DB00628,Clorazepate
,6415130,accumulation half-life,"Determination of diazepam and desmethyldiazepam plasma concentrations during the dosing period and for a withdrawal period indicated that accumulation half-life for both diazepam (7.8 days in obese vs. 3.1 days in normal subjects, P less than 0.05) and desmethyldiazepam (30.3 vs.",Prolonged accumulation of diazepam in obesity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),d,3.1,90012,DB00628,Clorazepate
,6415130,accumulation half-life,"Determination of diazepam and desmethyldiazepam plasma concentrations during the dosing period and for a withdrawal period indicated that accumulation half-life for both diazepam (7.8 days in obese vs. 3.1 days in normal subjects, P less than 0.05) and desmethyldiazepam (30.3 vs.",Prolonged accumulation of diazepam in obesity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),,30.3,90013,DB00628,Clorazepate
,6415130,steady-state plasma concentrations,"However, mean steady-state plasma concentrations of diazepam (68 vs. 67 ng/ml) and desmethyldiazepam (156 vs. 91 ng/ml) did not significantly differ between groups.",Prolonged accumulation of diazepam in obesity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),[ng] / [ml],68,90014,DB00628,Clorazepate
,6415130,steady-state plasma concentrations,"However, mean steady-state plasma concentrations of diazepam (68 vs. 67 ng/ml) and desmethyldiazepam (156 vs. 91 ng/ml) did not significantly differ between groups.",Prolonged accumulation of diazepam in obesity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),[ng] / [ml],67,90015,DB00628,Clorazepate
,6415130,steady-state plasma concentrations,"However, mean steady-state plasma concentrations of diazepam (68 vs. 67 ng/ml) and desmethyldiazepam (156 vs. 91 ng/ml) did not significantly differ between groups.",Prolonged accumulation of diazepam in obesity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),[ng] / [ml],156,90016,DB00628,Clorazepate
,6415130,steady-state plasma concentrations,"However, mean steady-state plasma concentrations of diazepam (68 vs. 67 ng/ml) and desmethyldiazepam (156 vs. 91 ng/ml) did not significantly differ between groups.",Prolonged accumulation of diazepam in obesity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),[ng] / [ml],91,90017,DB00628,Clorazepate
,6415130,elimination half-life,"Diazepam elimination half-life was greatly prolonged in the obese subjects (82 vs. 32 hours, P less than 0.005), with no change in total metabolic clearance (32 vs. 26 ml/min).",Prolonged accumulation of diazepam in obesity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),h,82,90018,DB00628,Clorazepate
,6415130,elimination half-life,"Diazepam elimination half-life was greatly prolonged in the obese subjects (82 vs. 32 hours, P less than 0.005), with no change in total metabolic clearance (32 vs. 26 ml/min).",Prolonged accumulation of diazepam in obesity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),h,32,90019,DB00628,Clorazepate
,6415130,total metabolic clearance,"Diazepam elimination half-life was greatly prolonged in the obese subjects (82 vs. 32 hours, P less than 0.005), with no change in total metabolic clearance (32 vs. 26 ml/min).",Prolonged accumulation of diazepam in obesity. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),[ml] / [min],32,90020,DB00628,Clorazepate
,6415130,total metabolic clearance,"Diazepam elimination half-life was greatly prolonged in the obese subjects (82 vs. 32 hours, P less than 0.005), with no change in total metabolic clearance (32 vs. 26 ml/min).",Prolonged accumulation of diazepam in obesity. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),[ml] / [min],26,90021,DB00628,Clorazepate
,6415130,volume of distribution,"Instead, a large increase in volume of distribution (228 vs. 70 liters, P less than 0.01) was the reason for prolongation of the elimination half-life.",Prolonged accumulation of diazepam in obesity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),l,228,90022,DB00628,Clorazepate
,6415130,volume of distribution,"Instead, a large increase in volume of distribution (228 vs. 70 liters, P less than 0.01) was the reason for prolongation of the elimination half-life.",Prolonged accumulation of diazepam in obesity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),l,70,90023,DB00628,Clorazepate
,6415130,elimination half-life,"Similarly for desmethyldiazepam, elimination half-life was prolonged in obese subjects (130 vs. 56 hours, P less than 0.01), without a change in total metabolic clearance (13.7 vs. 19.2 ml/min), due to increased volume of distribution (151 vs. 73 liters, P less than 0.01).",Prolonged accumulation of diazepam in obesity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),h,130,90024,DB00628,Clorazepate
,6415130,elimination half-life,"Similarly for desmethyldiazepam, elimination half-life was prolonged in obese subjects (130 vs. 56 hours, P less than 0.01), without a change in total metabolic clearance (13.7 vs. 19.2 ml/min), due to increased volume of distribution (151 vs. 73 liters, P less than 0.01).",Prolonged accumulation of diazepam in obesity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),h,56,90025,DB00628,Clorazepate
,6415130,total metabolic clearance,"Similarly for desmethyldiazepam, elimination half-life was prolonged in obese subjects (130 vs. 56 hours, P less than 0.01), without a change in total metabolic clearance (13.7 vs. 19.2 ml/min), due to increased volume of distribution (151 vs. 73 liters, P less than 0.01).",Prolonged accumulation of diazepam in obesity. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),[ml] / [min],13.7,90026,DB00628,Clorazepate
,6415130,total metabolic clearance,"Similarly for desmethyldiazepam, elimination half-life was prolonged in obese subjects (130 vs. 56 hours, P less than 0.01), without a change in total metabolic clearance (13.7 vs. 19.2 ml/min), due to increased volume of distribution (151 vs. 73 liters, P less than 0.01).",Prolonged accumulation of diazepam in obesity. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),[ml] / [min],19.2,90027,DB00628,Clorazepate
,6415130,volume of distribution,"Similarly for desmethyldiazepam, elimination half-life was prolonged in obese subjects (130 vs. 56 hours, P less than 0.01), without a change in total metabolic clearance (13.7 vs. 19.2 ml/min), due to increased volume of distribution (151 vs. 73 liters, P less than 0.01).",Prolonged accumulation of diazepam in obesity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),l,151,90028,DB00628,Clorazepate
,6415130,volume of distribution,"Similarly for desmethyldiazepam, elimination half-life was prolonged in obese subjects (130 vs. 56 hours, P less than 0.01), without a change in total metabolic clearance (13.7 vs. 19.2 ml/min), due to increased volume of distribution (151 vs. 73 liters, P less than 0.01).",Prolonged accumulation of diazepam in obesity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),l,73,90029,DB00628,Clorazepate
,2085227,Maximal nordiazepam concentrations,"Maximal nordiazepam concentrations ranged from 446 to 1,542 ng/ml (814 +/- 334 ng/ml), at 59 to 180 minutes (97.9 +/- 42.0 minutes) after a single oral dose of clorazepate.",Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),[ng] / [ml],"446 to 1,542",99260,DB00628,Clorazepate
,2085227,Maximal nordiazepam concentrations,"Maximal nordiazepam concentrations ranged from 446 to 1,542 ng/ml (814 +/- 334 ng/ml), at 59 to 180 minutes (97.9 +/- 42.0 minutes) after a single oral dose of clorazepate.",Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),[ng] / [ml],814,99261,DB00628,Clorazepate
,2085227,Maximal nordiazepam concentrations,"Maximal nordiazepam concentrations ranged from 927 to 1,460 ng/ml (1,308 +/- 187.6 ng/ml), at 120 to 239 minutes (153 +/- 57.9 minutes) after multiple oral doses of clorazepate.",Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),[ng] / [ml],"927 to 1,460",99262,DB00628,Clorazepate
,2085227,Maximal nordiazepam concentrations,"Maximal nordiazepam concentrations ranged from 927 to 1,460 ng/ml (1,308 +/- 187.6 ng/ml), at 120 to 239 minutes (153 +/- 57.9 minutes) after multiple oral doses of clorazepate.",Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),[ng] / [ml],"1,308",99263,DB00628,Clorazepate
,2085227,mean residence time,"Using data determined by the predictive equations method, the mean residence time after multiple doses (712 +/- 214 minutes) was longer (P less than 0.05) than after a single dose (527 +/- 95.8 minutes).",Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),min,712,99264,DB00628,Clorazepate
,2085227,mean residence time,"Using data determined by the predictive equations method, the mean residence time after multiple doses (712 +/- 214 minutes) was longer (P less than 0.05) than after a single dose (527 +/- 95.8 minutes).",Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),min,527,99265,DB00628,Clorazepate
,2085227,Oral volume of distribution,Oral volume of distribution after multiple doses of clorazepate (1.76 +/- 0.647 L/kg) was smaller (P less than 0.02) than after a single dose (3.18 +/- 1.52 L/kg).,Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),[l] / [kg],1.76,99266,DB00628,Clorazepate
,2085227,Oral volume of distribution,Oral volume of distribution after multiple doses of clorazepate (1.76 +/- 0.647 L/kg) was smaller (P less than 0.02) than after a single dose (3.18 +/- 1.52 L/kg).,Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),[l] / [kg],3.18,99267,DB00628,Clorazepate
,2085227,Oral clearance,Oral clearance after multiple doses of clorazepate (3.09 +/- 0.726 ml/min/kg) was less (P less than 0.001) than after a single dose (6.54 +/- 2.15 ml/min/kg).,Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),[ml] / [kg·min],3.09,99268,DB00628,Clorazepate
,2085227,Oral clearance,Oral clearance after multiple doses of clorazepate (3.09 +/- 0.726 ml/min/kg) was less (P less than 0.001) than after a single dose (6.54 +/- 2.15 ml/min/kg).,Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),[ml] / [kg·min],6.54,99269,DB00628,Clorazepate
,2085227,Absorption half-life,Absorption half-life after multiple doses (72 minutes) was longer (P less than 0.01) than after a single dose (33 minutes).,Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),min,72,99270,DB00628,Clorazepate
,2085227,Absorption half-life,Absorption half-life after multiple doses (72 minutes) was longer (P less than 0.01) than after a single dose (33 minutes).,Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),min,33,99271,DB00628,Clorazepate
,6811726,elimination half-life (t1/2),Obese subjects compared to controls had a prolonged desmethyldiazepam elimination half-life (t1/2) (154.1 hr versus 57.1 hr; p less than 0.005).,Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811726/),h,154.1,109254,DB00628,Clorazepate
,6811726,elimination half-life (t1/2),Obese subjects compared to controls had a prolonged desmethyldiazepam elimination half-life (t1/2) (154.1 hr versus 57.1 hr; p less than 0.005).,Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811726/),h,57.1,109255,DB00628,Clorazepate
,6811726,volume of distribution (Vd),"Assuming quantitative conversion of clorazepate to desmethyldiazepam and 100% systemic availability, volume of distribution (Vd) was greatly increased in the obese (158.8 liters versus 63.3 liters; p less than 0.001).",Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811726/),l,158.8,109256,DB00628,Clorazepate
,6811726,volume of distribution (Vd),"Assuming quantitative conversion of clorazepate to desmethyldiazepam and 100% systemic availability, volume of distribution (Vd) was greatly increased in the obese (158.8 liters versus 63.3 liters; p less than 0.001).",Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811726/),l,63.3,109257,DB00628,Clorazepate
,6811726,Vd,The value of Vd remained greater even after correction for body weight (1.52 liter/kg versus 0.94 liter/kg; p less than 0.005).,Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811726/),[l] / [kg],1.52,109258,DB00628,Clorazepate
,6811726,Vd,The value of Vd remained greater even after correction for body weight (1.52 liter/kg versus 0.94 liter/kg; p less than 0.005).,Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811726/),[l] / [kg],0.94,109259,DB00628,Clorazepate
,6811726,clearance,"However, clearance of desmethyldiazepam was not different between groups (13.2 ml/min in obese versus 13.4 ml/min in controls).",Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811726/),[ml] / [min],13.2,109260,DB00628,Clorazepate
,6811726,clearance,"However, clearance of desmethyldiazepam was not different between groups (13.2 ml/min in obese versus 13.4 ml/min in controls).",Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811726/),[ml] / [min],13.4,109261,DB00628,Clorazepate
,6813365,half-life,"In the control state, antipyrine half-life was longer in elderly than in young subjects (16.4 vs 11.0 hours), and metabolic clearance lower (0.48 vs 0.72 ml/min/kg).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),h,16.4,109996,DB00628,Clorazepate
,6813365,half-life,"In the control state, antipyrine half-life was longer in elderly than in young subjects (16.4 vs 11.0 hours), and metabolic clearance lower (0.48 vs 0.72 ml/min/kg).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),h,11.0,109997,DB00628,Clorazepate
,6813365,metabolic clearance,"In the control state, antipyrine half-life was longer in elderly than in young subjects (16.4 vs 11.0 hours), and metabolic clearance lower (0.48 vs 0.72 ml/min/kg).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),[ml] / [kg·min],0.48,109998,DB00628,Clorazepate
,6813365,metabolic clearance,"In the control state, antipyrine half-life was longer in elderly than in young subjects (16.4 vs 11.0 hours), and metabolic clearance lower (0.48 vs 0.72 ml/min/kg).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),[ml] / [kg·min],0.72,109999,DB00628,Clorazepate
,6813365,half-life,"However, coadministration of cimetidine prolonged antipyrine half-life to a similar extent in elderly and in young groups (150 and 153 per cent of control) and reduced metabolic clearance to a similar extent in both (79 vs 69 per cent of control) groups.",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,150,110000,DB00628,Clorazepate
,6813365,half-life,"However, coadministration of cimetidine prolonged antipyrine half-life to a similar extent in elderly and in young groups (150 and 153 per cent of control) and reduced metabolic clearance to a similar extent in both (79 vs 69 per cent of control) groups.",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,153,110001,DB00628,Clorazepate
,6813365,metabolic clearance,"However, coadministration of cimetidine prolonged antipyrine half-life to a similar extent in elderly and in young groups (150 and 153 per cent of control) and reduced metabolic clearance to a similar extent in both (79 vs 69 per cent of control) groups.",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,79,110002,DB00628,Clorazepate
,6813365,metabolic clearance,"However, coadministration of cimetidine prolonged antipyrine half-life to a similar extent in elderly and in young groups (150 and 153 per cent of control) and reduced metabolic clearance to a similar extent in both (79 vs 69 per cent of control) groups.",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,69,110003,DB00628,Clorazepate
,6813365,half-life,"As in the case of antipyrine, cimetidine prolonged desmethyldiazepam half-life similarly in young and elderly groups (175 vs 164 per cent of control) and similarly reduced metabolic clearance (51 vs 65 per cent of control).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,175,110004,DB00628,Clorazepate
,6813365,half-life,"As in the case of antipyrine, cimetidine prolonged desmethyldiazepam half-life similarly in young and elderly groups (175 vs 164 per cent of control) and similarly reduced metabolic clearance (51 vs 65 per cent of control).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,164,110005,DB00628,Clorazepate
,6813365,metabolic clearance,"As in the case of antipyrine, cimetidine prolonged desmethyldiazepam half-life similarly in young and elderly groups (175 vs 164 per cent of control) and similarly reduced metabolic clearance (51 vs 65 per cent of control).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,51,110006,DB00628,Clorazepate
,6813365,metabolic clearance,"As in the case of antipyrine, cimetidine prolonged desmethyldiazepam half-life similarly in young and elderly groups (175 vs 164 per cent of control) and similarly reduced metabolic clearance (51 vs 65 per cent of control).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,65,110007,DB00628,Clorazepate
,28870,peak measured concentration,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),[ng] / [ml],273,115120,DB00628,Clorazepate
,28870,peak measured concentration,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),[ng] / [ml],188,115121,DB00628,Clorazepate
,28870,time of peak concentration,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),h,1.8,115122,DB00628,Clorazepate
,28870,time of peak concentration,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),h,2.8,115123,DB00628,Clorazepate
,28870,apparent absorption half-life,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),min,14.8,115124,DB00628,Clorazepate
,28870,apparent absorption half-life,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),min,30.7,115125,DB00628,Clorazepate
,28870,area under the 48-hr plasma concentration curve,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),[ng] / [h·ml],"6,028",115126,DB00628,Clorazepate
,28870,area under the 48-hr plasma concentration curve,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),[ng] / [h·ml],"5,433",115127,DB00628,Clorazepate
,2879960,volume of distribution,"In control vs propranolol treatment conditions, there was no significant difference in desmethyldiazepam volume of distribution (1.27 vs 1.23 liters/kg) or in free fraction in serum (1.83 vs 1.80% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[l] / [kg],1.27,175186,DB00628,Clorazepate
,2879960,volume of distribution,"In control vs propranolol treatment conditions, there was no significant difference in desmethyldiazepam volume of distribution (1.27 vs 1.23 liters/kg) or in free fraction in serum (1.83 vs 1.80% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[l] / [kg],1.23,175187,DB00628,Clorazepate
,2879960,free fraction in serum,"In control vs propranolol treatment conditions, there was no significant difference in desmethyldiazepam volume of distribution (1.27 vs 1.23 liters/kg) or in free fraction in serum (1.83 vs 1.80% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),%·unbound,1.83,175188,DB00628,Clorazepate
,2879960,free fraction in serum,"In control vs propranolol treatment conditions, there was no significant difference in desmethyldiazepam volume of distribution (1.27 vs 1.23 liters/kg) or in free fraction in serum (1.83 vs 1.80% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),%·unbound,1.80,175189,DB00628,Clorazepate
,2879960,half-life,"There was a small although statistically significant prolongation of desmethyldiazepam half-life (55 vs 61 h, P less than 0.05) and reduction in clearance (0.281 vs 0.247 ml/min/kg, P less than 0.02) attributable to propranolol.",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),h,55,175190,DB00628,Clorazepate
,2879960,half-life,"There was a small although statistically significant prolongation of desmethyldiazepam half-life (55 vs 61 h, P less than 0.05) and reduction in clearance (0.281 vs 0.247 ml/min/kg, P less than 0.02) attributable to propranolol.",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),h,61,175191,DB00628,Clorazepate
,2879960,clearance,"There was a small although statistically significant prolongation of desmethyldiazepam half-life (55 vs 61 h, P less than 0.05) and reduction in clearance (0.281 vs 0.247 ml/min/kg, P less than 0.02) attributable to propranolol.",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[ml] / [kg·min],0.281,175192,DB00628,Clorazepate
,2879960,clearance,"There was a small although statistically significant prolongation of desmethyldiazepam half-life (55 vs 61 h, P less than 0.05) and reduction in clearance (0.281 vs 0.247 ml/min/kg, P less than 0.02) attributable to propranolol.",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[ml] / [kg·min],0.247,175193,DB00628,Clorazepate
,2879960,volume of distribution,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[l] / [kg],1.29,175194,DB00628,Clorazepate
,2879960,volume of distribution,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[l] / [kg],1.34,175195,DB00628,Clorazepate
,2879960,elimination half-life,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),h,55,175196,DB00628,Clorazepate
,2879960,elimination half-life,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),h,59,175197,DB00628,Clorazepate
,2879960,clearance,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[ml] / [kg·min],0.284,175198,DB00628,Clorazepate
,2879960,clearance,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[ml] / [kg·min],0.276,175199,DB00628,Clorazepate
,2879960,free fraction in serum,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),%·unbound,1.96,175200,DB00628,Clorazepate
,2879960,free fraction in serum,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),%·unbound,1.92,175201,DB00628,Clorazepate
,13089,serum half-life (t0.5beta),"Pharmacokinetic analysis of the data according to a two-compartment open model with first-order absorption indicated that the serum half-life (t0.5beta) of nordiazepam, the major biotransformation product present in serum, was about 48 hours and served as a basis for the design of a multiple-dose steady-state study.",Steady-state bioavailability of two clorazepate dipotassium dosage forms. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13089/),h,48,180381,DB00628,Clorazepate
,13089,minimum steady-state serum levels,Multiple-dose administration of the tablet and divided-capsule regimen to two groups of subjects for ten days indicated each dosage form yielded similar minimum steady-state serum levels of about 0.6 micrograms/ml which plateaued following seven days of drug administration.,Steady-state bioavailability of two clorazepate dipotassium dosage forms. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13089/),[μg] / [ml],0.6,180382,DB00628,Clorazepate
,6137019,bioavailability,The bioavailability was almost 100% after IM administration.,Pharmacokinetics of chlorazepate after intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137019/),%,100,189043,DB00628,Clorazepate
,6137019,plasma half lives,The plasma half lives of DPC and DMD were independent of the form of administration (2.42 and 46.0 h respectively after IV and 2.29 and 45.1 h respectively after IM injection).,Pharmacokinetics of chlorazepate after intravenous and intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137019/),h,2.42,189044,DB00628,Clorazepate
,6137019,plasma half lives,The plasma half lives of DPC and DMD were independent of the form of administration (2.42 and 46.0 h respectively after IV and 2.29 and 45.1 h respectively after IM injection).,Pharmacokinetics of chlorazepate after intravenous and intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137019/),h,46.0,189045,DB00628,Clorazepate
,6137019,plasma half lives,The plasma half lives of DPC and DMD were independent of the form of administration (2.42 and 46.0 h respectively after IV and 2.29 and 45.1 h respectively after IM injection).,Pharmacokinetics of chlorazepate after intravenous and intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137019/),h,2.29,189046,DB00628,Clorazepate
,6137019,plasma half lives,The plasma half lives of DPC and DMD were independent of the form of administration (2.42 and 46.0 h respectively after IV and 2.29 and 45.1 h respectively after IM injection).,Pharmacokinetics of chlorazepate after intravenous and intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137019/),h,45.1,189047,DB00628,Clorazepate
,8368611,maximal nordiazepam concentrations,"After a single oral dose of clorazepate, maximal nordiazepam concentrations ranged from 569.6 to 1,387.9 ng/ml (mean, 880.2 +/- 248.9 ng/ml) and were detected 16.8 to 131.4 minutes (mean, 85.2 +/- 36 minutes) after dosing.",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ng] / [ml],"569.6 to 1,387.9",189693,DB00628,Clorazepate
,8368611,maximal nordiazepam concentrations,"After a single oral dose of clorazepate, maximal nordiazepam concentrations ranged from 569.6 to 1,387.9 ng/ml (mean, 880.2 +/- 248.9 ng/ml) and were detected 16.8 to 131.4 minutes (mean, 85.2 +/- 36 minutes) after dosing.",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ng] / [ml],880.2,189694,DB00628,Clorazepate
,8368611,maximal nordiazepam concentrations,"After administration of phenobarbital for 44 consecutive days, maximal nordiazepam concentrations were significantly (P < 0.01) lower, ranging from 209.6 to 698.5 ng/ml (mean, 399.3 +/- 155.6 ng/ml) at 68.4 to 145.8 minutes (mean, 93 +/- 25.8 minutes) after dosing.",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ng] / [ml],209.6 to 698.5,189695,DB00628,Clorazepate
,8368611,maximal nordiazepam concentrations,"After administration of phenobarbital for 44 consecutive days, maximal nordiazepam concentrations were significantly (P < 0.01) lower, ranging from 209.6 to 698.5 ng/ml (mean, 399.3 +/- 155.6 ng/ml) at 68.4 to 145.8 minutes (mean, 93 +/- 25.8 minutes) after dosing.",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ng] / [ml],39,189696,DB00628,Clorazepate
,8368611,area under the curve (AUC),"Mean area under the curve (AUC) on day 1 (mean, 3.37 +/- 0.598 ng.min/ml) was significantly (P < 0.001) greater than AUC on day 44 (1.66 +/- 0.308 ng.min/ml).",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[min·ng] / [ml],3.37,189697,DB00628,Clorazepate
,8368611,AUC,"Mean area under the curve (AUC) on day 1 (mean, 3.37 +/- 0.598 ng.min/ml) was significantly (P < 0.001) greater than AUC on day 44 (1.66 +/- 0.308 ng.min/ml).",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[min·ng] / [ml],1.66,189698,DB00628,Clorazepate
,8368611,Oral clearance,"Oral clearance was significantly (P < 0.01) greater on day 44 (12.44 +/- 2.55 ml/min/kg), compared with that on day 1 (6.16 +/- 1.35 ml/min/kg).",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ml] / [kg·min],12.44,189699,DB00628,Clorazepate
,8368611,Oral clearance,"Oral clearance was significantly (P < 0.01) greater on day 44 (12.44 +/- 2.55 ml/min/kg), compared with that on day 1 (6.16 +/- 1.35 ml/min/kg).",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ml] / [kg·min],6.16,189700,DB00628,Clorazepate
,2906643,volume of distribution (Vd),"Mean kinetic variables were volume of distribution (Vd), 90 liters; elimination half-life (t1/2), 93 hours; and clearance, 12.3 mL/min.","Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906643/),l,90,213155,DB00628,Clorazepate
,2906643,elimination half-life (t1/2),"Mean kinetic variables were volume of distribution (Vd), 90 liters; elimination half-life (t1/2), 93 hours; and clearance, 12.3 mL/min.","Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906643/),h,93,213156,DB00628,Clorazepate
,2906643,clearance,"Mean kinetic variables were volume of distribution (Vd), 90 liters; elimination half-life (t1/2), 93 hours; and clearance, 12.3 mL/min.","Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906643/),[ml] / [min],12.3,213157,DB00628,Clorazepate
,2906643,Vd,"Mean kinetic variables were Vd, 180 liters; t1/2, 83 hours; and clearance, 28 mL/min.","Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906643/),l,180,213158,DB00628,Clorazepate
,2906643,t1/2,"Mean kinetic variables were Vd, 180 liters; t1/2, 83 hours; and clearance, 28 mL/min.","Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906643/),h,83,213159,DB00628,Clorazepate
,2906643,clearance,"Mean kinetic variables were Vd, 180 liters; t1/2, 83 hours; and clearance, 28 mL/min.","Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906643/),[ml] / [min],28,213160,DB00628,Clorazepate
,2906643,systemic availability,"After oral administration of DMDZ in tablet form (10 mg), or of clorazepate dipotassium in capsule form (15 mg), systemic availability of DMDZ from each of the oral dosage forms was not significantly different from 100%.","Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906643/),%,100,213161,DB00628,Clorazepate
,19801,plasma half-life (t1/2),"The plasma half-life (t1/2), the elimination coefficient (Kbeta), the concentration (Css), and the apparent volume of distribution (Vbeta) were calculated at steady state, and the mean values +/- SEM were 53 +/- 6 h, 0.0147 +/- 0.0013 h-1, 884 +/- 73 ng/ml, and 1.13 +/- 0.08 1/kg, respectively.",Pharmacokinetics of N-desmethyldiazepam in healthy volunteers after single daily doses of dipotassium chlorazepate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801/),h,53,237710,DB00628,Clorazepate
,19801,elimination coefficient (Kbeta),"The plasma half-life (t1/2), the elimination coefficient (Kbeta), the concentration (Css), and the apparent volume of distribution (Vbeta) were calculated at steady state, and the mean values +/- SEM were 53 +/- 6 h, 0.0147 +/- 0.0013 h-1, 884 +/- 73 ng/ml, and 1.13 +/- 0.08 1/kg, respectively.",Pharmacokinetics of N-desmethyldiazepam in healthy volunteers after single daily doses of dipotassium chlorazepate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801/),1/[h],0.0147,237711,DB00628,Clorazepate
,19801,elimination coefficient (Kbeta),"The plasma half-life (t1/2), the elimination coefficient (Kbeta), the concentration (Css), and the apparent volume of distribution (Vbeta) were calculated at steady state, and the mean values +/- SEM were 53 +/- 6 h, 0.0147 +/- 0.0013 h-1, 884 +/- 73 ng/ml, and 1.13 +/- 0.08 1/kg, respectively.",Pharmacokinetics of N-desmethyldiazepam in healthy volunteers after single daily doses of dipotassium chlorazepate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801/),[ng] / [ml],884,237712,DB00628,Clorazepate
,19801,concentration (Css),"The plasma half-life (t1/2), the elimination coefficient (Kbeta), the concentration (Css), and the apparent volume of distribution (Vbeta) were calculated at steady state, and the mean values +/- SEM were 53 +/- 6 h, 0.0147 +/- 0.0013 h-1, 884 +/- 73 ng/ml, and 1.13 +/- 0.08 1/kg, respectively.",Pharmacokinetics of N-desmethyldiazepam in healthy volunteers after single daily doses of dipotassium chlorazepate. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801/),1/[h],0.0147,237713,DB00628,Clorazepate
,19801,apparent volume of distribution (Vbeta),"The plasma half-life (t1/2), the elimination coefficient (Kbeta), the concentration (Css), and the apparent volume of distribution (Vbeta) were calculated at steady state, and the mean values +/- SEM were 53 +/- 6 h, 0.0147 +/- 0.0013 h-1, 884 +/- 73 ng/ml, and 1.13 +/- 0.08 1/kg, respectively.",Pharmacokinetics of N-desmethyldiazepam in healthy volunteers after single daily doses of dipotassium chlorazepate. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801/),[1] / [kg],1.13,237714,DB00628,Clorazepate
,2908106,ED50,"The ED50 of the drug was 12 mg/kg at 1 min against pentetrazole-induced convulsions (45 mg/kg i.v.), it reached a minimum at 1 h (2.0 mg/kg) and rose to 2.7 mg/kg at 2 h.","Clorazepate, correlation between metabolism and anticonvulsant activity. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908106/),[mg] / [kg],12,239133,DB00628,Clorazepate
,2908106,ED50,"The ED50 of the drug was 12 mg/kg at 1 min against pentetrazole-induced convulsions (45 mg/kg i.v.), it reached a minimum at 1 h (2.0 mg/kg) and rose to 2.7 mg/kg at 2 h.","Clorazepate, correlation between metabolism and anticonvulsant activity. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908106/),[mg] / [kg],2.7,239134,DB00628,Clorazepate
,37089,absorption half life,Mean pharmacokinetic parameters for clorazepate were absorption half life 0.77 h in pregnant women and 0.56 h in non-pregnant women; elimination half life 1.3 h in pregnant women and 2.0 h in non-pregnant women; volume of distribution: 0.43 1 . kg-1 in the pregnant women and 0.33 1 . kg-1 in non-pregnant women.,Pharmacokinetics of clorazepate in pregnant and non-pregnant women. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/37089/),h,0.77,245841,DB00628,Clorazepate
,37089,absorption half life,Mean pharmacokinetic parameters for clorazepate were absorption half life 0.77 h in pregnant women and 0.56 h in non-pregnant women; elimination half life 1.3 h in pregnant women and 2.0 h in non-pregnant women; volume of distribution: 0.43 1 . kg-1 in the pregnant women and 0.33 1 . kg-1 in non-pregnant women.,Pharmacokinetics of clorazepate in pregnant and non-pregnant women. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/37089/),h,0.56,245842,DB00628,Clorazepate
,37089,elimination half life,Mean pharmacokinetic parameters for clorazepate were absorption half life 0.77 h in pregnant women and 0.56 h in non-pregnant women; elimination half life 1.3 h in pregnant women and 2.0 h in non-pregnant women; volume of distribution: 0.43 1 . kg-1 in the pregnant women and 0.33 1 . kg-1 in non-pregnant women.,Pharmacokinetics of clorazepate in pregnant and non-pregnant women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/37089/),h,1.3,245843,DB00628,Clorazepate
,37089,elimination half life,Mean pharmacokinetic parameters for clorazepate were absorption half life 0.77 h in pregnant women and 0.56 h in non-pregnant women; elimination half life 1.3 h in pregnant women and 2.0 h in non-pregnant women; volume of distribution: 0.43 1 . kg-1 in the pregnant women and 0.33 1 . kg-1 in non-pregnant women.,Pharmacokinetics of clorazepate in pregnant and non-pregnant women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/37089/),h,2.0,245844,DB00628,Clorazepate
,37089,volume of distribution,Mean pharmacokinetic parameters for clorazepate were absorption half life 0.77 h in pregnant women and 0.56 h in non-pregnant women; elimination half life 1.3 h in pregnant women and 2.0 h in non-pregnant women; volume of distribution: 0.43 1 . kg-1 in the pregnant women and 0.33 1 . kg-1 in non-pregnant women.,Pharmacokinetics of clorazepate in pregnant and non-pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/37089/),[1] / [kg],0.43,245845,DB00628,Clorazepate
,37089,volume of distribution,Mean pharmacokinetic parameters for clorazepate were absorption half life 0.77 h in pregnant women and 0.56 h in non-pregnant women; elimination half life 1.3 h in pregnant women and 2.0 h in non-pregnant women; volume of distribution: 0.43 1 . kg-1 in the pregnant women and 0.33 1 . kg-1 in non-pregnant women.,Pharmacokinetics of clorazepate in pregnant and non-pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/37089/),[1] / [kg],0.33,245846,DB00628,Clorazepate
,37089,half life of elimination,Nordiazepam reached its peak concentration within 12 h after dosing; its mean half life of elimination was 180 h in pregnant women and 60 h in non-pregnant women.,Pharmacokinetics of clorazepate in pregnant and non-pregnant women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/37089/),h,180,245847,DB00628,Clorazepate
,37089,half life of elimination,Nordiazepam reached its peak concentration within 12 h after dosing; its mean half life of elimination was 180 h in pregnant women and 60 h in non-pregnant women.,Pharmacokinetics of clorazepate in pregnant and non-pregnant women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/37089/),h,60,245848,DB00628,Clorazepate
,6124654,volume of distribution,"After a single 20-mg intravenous dose of CZP, mean kinetic variables for DMDZ were: volume of distribution, 1.24 l/kg; elimination half-life, 65 h; total clearance, 0.24 ml/min/kg.","Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124654/),[l] / [kg],1.24,258525,DB00628,Clorazepate
,6124654,elimination half-life,"After a single 20-mg intravenous dose of CZP, mean kinetic variables for DMDZ were: volume of distribution, 1.24 l/kg; elimination half-life, 65 h; total clearance, 0.24 ml/min/kg.","Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124654/),h,65,258526,DB00628,Clorazepate
,6124654,total clearance,"After a single 20-mg intravenous dose of CZP, mean kinetic variables for DMDZ were: volume of distribution, 1.24 l/kg; elimination half-life, 65 h; total clearance, 0.24 ml/min/kg.","Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124654/),[ml] / [kg·min],0.24,258527,DB00628,Clorazepate
,6124654,peak plasma level,"After oral administration of 20 mg CZP, appearance of DMDZ in the circulation was rapid; the mean peak plasma level was 356 ng/ml, reached an average of 0.9 h after dosage.","Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124654/),[ng] / [ml],356,258528,DB00628,Clorazepate
,6124654,peak DMDZ levels,"Mean peak DMDZ levels were 290 ng/ml, reaching an average of 2.7 h after dosage.","Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124654/),[ng] / [ml],290,258529,DB00628,Clorazepate
,6119204,half life of elimination (t1/2 beta),The half life of elimination (t1/2 beta) was significantly longer in the non-smoking volunteers than in the smokers: 54.7 +17.7 versus 29.8 +9.9 h (p less than 0.05).,Pharmacokinetics of N-desmethyldiazepam after a single oral dose of clorazepate: the effect of smoking. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119204/),h,54.7,271576,DB00628,Clorazepate
,6119204,half life of elimination (t1/2 beta),The half life of elimination (t1/2 beta) was significantly longer in the non-smoking volunteers than in the smokers: 54.7 +17.7 versus 29.8 +9.9 h (p less than 0.05).,Pharmacokinetics of N-desmethyldiazepam after a single oral dose of clorazepate: the effect of smoking. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119204/),h,29.8,271577,DB00628,Clorazepate
,6119204,Peak plasma concentrations (Cmax),"Peak plasma concentrations (Cmax) were higher in non-smokers than in smokers, 413 +106 micrograms/l and 245 +50 micrograms/l, respectively (p less than 0.05).",Pharmacokinetics of N-desmethyldiazepam after a single oral dose of clorazepate: the effect of smoking. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119204/),[μg] / [l],413,271578,DB00628,Clorazepate
,6119204,Peak plasma concentrations (Cmax),"Peak plasma concentrations (Cmax) were higher in non-smokers than in smokers, 413 +106 micrograms/l and 245 +50 micrograms/l, respectively (p less than 0.05).",Pharmacokinetics of N-desmethyldiazepam after a single oral dose of clorazepate: the effect of smoking. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119204/),[μg] / [l],245,271579,DB00628,Clorazepate
